Sinapic acid ameliorates bleomycin-induced lung fibrosis in rats

Biomed Pharmacother. 2018 Dec:108:224-231. doi: 10.1016/j.biopha.2018.09.032. Epub 2018 Sep 13.

Abstract

Background: Pulmonary fibrosis is a multifaceted disease with high mortality and morbidity, and it is commonly nonresponsive to conventional therapy.

Purpose: We explore the possible discourse of sinapic acid (SA) against the prevention of bleomycin (BLM)-instigated lung fibrosis in rats through modulation of Nrf2/HO-1 and NF-κB signaling pathways.

Design/methods: Lung fibrosis was persuaded in Sprague-Dawley rats by a single intratracheal BLM (6.5 U/kg) injection. Then, these rats were treated with SA (10 and 20 mg/kg, p.o.) for 28 days. The normal control rats provided saline as a substitute of BLM. The lung function and biochemical, histopathological, and molecular alterations were studied in serum, bronchoalveolar lavage fluid (BALF), and the lungs tissues.

Results: SA treatment significantly restored BLM-induced alterations in body weight index and serum biomarkers [lactate dehydrogenase (LDH) and alkaline phosphatase (ALP)]. SA (10 and 20 mg/kg) treatment appeared to show a pneumoprotective effect through upregulation of antioxidant status, downregulation of inflammatory cytokines and MMP-7 expression, and reduction of collagen accumulation (hydroxyproline). Nrf2, HO-1, and TGF-β expression was downregulated in BLM-induced fibrosis model, while the reduced expression levels were significantly and dose-dependently upregulated by SA (10 and 20 mg/kg) treatment. We demonstrated that SA ameliorates BLM-induced lung injuries through inhibition of apoptosis and induction of Nrf2/HO-1-mediated antioxidant enzymes via NF-κB inhibition. The histopathological findings also revealed that SA treatment (10 and 20 mg/kg) significantly ameliorated BLM-induced lung injury.

Conclusion: The present results showed the ability of SA to restore the antioxidant system and to inhibit oxidative stress, proinflammatory cytokines, extracellular matrix, and TGF-β. This is first report demonstrating that SA amoleriates BLM induced lung injuries through inhibition of apoptosis and induction of Nrf2 and HO-1 mediated antioxidant enzyme via NF-κB inhibition. The histopathological finding reveals that SA treatment (10 and 20 mg/kg) significantly ameliorates BLM induced lung injuries.

Keywords: Extracellular matrix deposition; Inflammation; Lung fibrosis; Sinapic acid.

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Apoptosis / drug effects
  • Biomarkers / metabolism
  • Bleomycin
  • Bronchoalveolar Lavage Fluid / cytology
  • Coumaric Acids / pharmacology
  • Coumaric Acids / therapeutic use*
  • Disease Models, Animal
  • Heme Oxygenase-1 / metabolism
  • Hydroxyproline / metabolism
  • Inflammation / pathology
  • Lung / drug effects
  • Lung / enzymology
  • Lung / pathology
  • Matrix Metalloproteinase 7 / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • NF-kappa B / metabolism
  • Organ Size / drug effects
  • Oxidative Stress / drug effects
  • Pulmonary Fibrosis / blood
  • Pulmonary Fibrosis / chemically induced
  • Pulmonary Fibrosis / drug therapy*
  • Pulmonary Fibrosis / pathology
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta / metabolism
  • Weight Gain / drug effects

Substances

  • Antioxidants
  • Biomarkers
  • Coumaric Acids
  • NF-E2-Related Factor 2
  • NF-kappa B
  • Transforming Growth Factor beta
  • Bleomycin
  • sinapinic acid
  • Heme Oxygenase-1
  • Matrix Metalloproteinase 7
  • Hydroxyproline